Skip to main content

Oncología integrativa - Bibliografía

Referencias: Oncología integrativa

Dr. Santos Martín

  1. Harguindey, S.; Henderson, E.S.; Naeher, C. Effects of systemic acidification of mice with Sarcoma 180. Cancer Res. 1979, 39, 4364–4371.
  2. Parfentjev, A.; Devrient, W.; Suntzeff, V.D.; Sokoloff, B. The Influence of Various Preparations of Lactic Acid on Transplanted Tumors: I. Action on Sarcoma 39. Cancer Res. 1932, 16, 366–376.
  3. Fenton TR, Huang T Systematic review of the association between dietary acid load, alkaline water and cancer BMJ Open 2016; 6:e 010438. doi: 10.1136/bmjopen-2015-010438
  4. Paradigm shift in cancer treatment: Cancer treatment as a metabolic disease–fusion of Eastern and Wester medicine R Hamaguchi, H Wada - Journal of Traditional Chinese Medical Sciences, 2017 - Elsevier
  5. Song, M. & Chan, A.T. Curr Colorectal Cancer Rep (2017) 13: 429. https://doi.org/10.1007/s11888-017-0389-y
  6. Y. Makino, R. Kanno, T. Ito, K. Higashino, M. Taniguchi. Predominant expression of invariant v alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int Immunol, 7 (1995), pp. 1157-1161
  7. El papel del infiltrado inflamatorio en tumores: dos caras de una misma moneda Silvina Gazzaniga. Revista QuímicaViva- Número 1, año 6, mayo 2007-
  8. Roithmaier S, Haydon AM, Loi S, et al. Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience. J Heart Lung Transplant 2007;26:845-9.
  9. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000;356: 1795-9.
  10. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
  11. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors
  12. predict clinical outcome. Science 2006;313:1960-4.
  13. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes
  14. is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007;67:354-61.
  15. Kohrt HE, Nouri N, Nowels K, Johnson D, Holmes S, Lee PP. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005;2(9):e284
  16. Sharma P, Shen Y, Wen S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A 2007;104:3967-72
  17. Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007;13:388- 97.
  18. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu
  19. Rev Immunol 2007;25:267-96.
  20. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40.
  21. Liu VC, Wong LY, Jang T, et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007;178:2883-92.
  22. Nagaraj S, Gabrilovich DI. Myeloidderived suppressor cells. Adv Exp Med Biol 2007;601:213-23.
  23. Fournie JJ, Sicard H, Poupot M et al. What lessons can be learned from gammadelta T cell‐based cancer immunotherapy trials?Cell Mol Immunol 2013; 10: 35– 41.
  24. Baker GJ, Chockley P, Yadav VNet al. Natural killer cells eradicate galectin‐1‐deficient glioma in the absence of adaptive immunity. Cancer Res 2014; 74: 5079– 5090.
  25. Wang L, Yi T, Kortylewski Met al. IL‐17 can promote tumor growth through an IL‐6‐Stat3 signaling pathway. J Exp Med 2009; 206: 1457– 1464.
  26. Eur J Cancer.2006 Apr;42(6):768-78. Epub 2006 Feb 28. Cancer CXC chemokine networks and tumour angiogenesis. Strieter RM1, Burdick MD, Mestas J, Gomperts B, Keane MP, Belperio JA.
  27. Wong D.Y.Q. (2018) Induction of Immunogenic Cell Death by Chemotherapeutic Platinum Complexes. In: Rethinking Platinum Anticancer Drug Design: Towards Targeted and Immuno-chemotherapeutic Approaches. Springer Theses (Recognizing Outstanding Ph.D. Research). Springer, Singapore
  28. Metronomic chemotherapy and immunotherapy in cancer treatment . Yu-LiChenabc, Ming-ChengChangcWen-FangChengcde Cancer Letters Volume 400, 1 August 2017, Pages 282-292
  29. Kleef R., Hager E.D. (2006) Fever, Pyrogens and Cancer. In: Hyperthermia in Cancer Treatment: A Primer. Medical Intelligence Unit. Springer, Boston, MA
  30. Rybiński Mikołaj, Szymańska Zuzanna, Lasota Sławomirand Gambin Anna Modelling the efficacy of hyperthermia treatment10J. R. Soc. Interface
  31. Zhang, T., Pan, Q., Xiao, S., Li, L., & Xue, M. (2016). Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer. Oncology Letters, 11, 3287-3292. https://doi.org/10.3892/ol.2016.4414
  32. Ishikawa T. (2016) Hyperthermia Combined with Chemotherapy: Pancreatic Cancer. In: Kokura S., Yoshikawa T., Ohnishi T. (eds) Hyperthermic Oncology from Bench to Bedside. Springer, Singapore
  33. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–33
  34. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 1981; 256: 8699–704.
  35. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 2012; 21: 297–308.
  36. Alberts B, Bray D, Hopkin K, Johnson A, Lewis A, Raff M, et al.Comunicación celular. En: Alberts B, Bray D, Hopkin K, JohnsonA, Lewis J, Raff M, Roberts K, Walter P, Introducción a la Biología Celular. 3th ed Madrid: Médica Panamericana; 2011.p. 533-72
  37. Possibly up to four NADPH molecules per glucose can be produced if the products of the pentose phosphate shunt are metabolized via the TCA cycle and malic enzyme or cytosolic isocitrate dehydrogenase 1 (IDH1) to generate two additional NADPH molecules
  38. Hidratos de carbono, metabolismo de la glucosa y cáncer. Endocrinología y Nutrición Vol. 53 Nr 4 pag: 252-255 (Abril 2006) J. Pérez-Guisado Departamento de Medicina. Facultad de Medicina. Universidad de Córdoba. Córdoba. España
  39. A ketogenic diet exerts beneficial effects on body composition of cancer patients during radiotherapy: An interim analysis of the KETOCOMP study Citation DataJournal of Traditional and Complementary Medicine, ISSN: 2225-4110 (2019)
  40. Weber DD, Aminazdeh-Gohari S, Kofler B. Ketogenic diet in cancer therapy. Aging (Albany NY). 2018 Feb 11;10(2):164-165. doi: 10.18632/aging.101382. PMID: 29443693; PMCID: PMC5842847.
  41. Fasting and Caloric Restriction in Cancer Pre vention and Treatment. Brandhorst S1, Longo VD2,3. Recent Results Cancer Res.2016;207:241-66. doi: 10.1007/978-3-319-42118-6_12.
  42. Quercetin inhibits glucose transport by binding to an exofacial site on GLUT1 Kathryn E. Hamilton, Janelle F. Rekman, Leesha K. Gunnink, Brianna M. Busscher, Jordan L. Scott, Andrew M. Tidball, Nathan R. Stehouwer, Grace N. Johnecheck, Brendan D. Looyenga, Larry L. Louters Biochimie. 2018 Aug; 151: 107–114. Published online 2018 May 29. doi: 10.1016/j.biochi.2018.05.012 PMCID: PMC6035882
  43. Repurposing metformin for the prevention of cancer and cancer recurrence Heckman-Stoddard, B.M., DeCensi, A., Sahasrabuddhe, V.V. et al. Diabetologia (2017) 60: 1639. https://doi.org/10.1007/s00125-017-4372-6
  44. C. Coyle, F. H. Cafferty, C. Vale, R. E. Langley, Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis, Annals of Oncology, Volume 27, Issue 12, December 2016, Pages 2184–2195, https://doi.org/10.1093/annonc/mdw410
  45. Liu Q, Yuan W, Tong D, et al. Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis. Oncotarget. 2016;7(19):28235–28246. doi:10.18632/oncotarget.8595
  46. Wang X, Chen K, Yu Y, et al. Metformin sensitizes lung cancer cells to treatment by the tyrosine kinase inhibitor erlotinib. Oncotarget. 2017;8(65):109068–109078. Published 2017 Nov 21. doi:10.18632/oncotarget.22596
  47. Potential applications for biguanides in oncology Michael Pollak Published September 3, 2013 J Clin Invest. 2013;123(9):3693-3700. https://doi.org/10.1172/JCI67232
  48. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells. Antonio F.Santidrián, Diana M. González-Gironès, Daniel Iglesias-Serret, Llorenç Coll-Mulet, Ana M. Cosialls, Mercè de Frias, Clara Campàs, Eva González-Barca, Esther Alonso, Verena Labi, Benoit Viollet, Adalberto Benito, Gabriel Pons, Andreas Villunger, Joan Gil Blood Oct 2010, 116 (16) 3023-3032; DOI: 10.1182/blood-2010-05-283960
  49. Vaupel, P. & Mayer, A. Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinical implications. Adv. Exp. Med. Biol. 812, 19–24 (2014).
  50. S. Harguindey, Use of Na+/H+ antiporter inhibitors as a novel approach tocancer treatment, in: Amiloride and Its Analogs: Unique Cation TransportInhibitors, VCH Publishers Inc., New York, 1992, pp. 317–334.
  51. S. Harguindey, J.L. Pedraz, R. García Ca˜nero, J. Pérez de Diego, E.J. Cragoe Jr.,Hydrogen ion-dependent oncogenesis and parallel new avenues to cancerprevention and treatment using a H(+)-mediated unifying approach:pH-related and pH-unrelated mechanisms, Crit. Rev. Oncog. 6 (1) (1995) 1–33
  52. M.A. McBrian, I.S. Behbahan, R. Ferrari, et al., Histone acetylation regulatesintracellular pH, Mol. Cell 49 (2) (2013) 310–321, http://dx.doi.org/10.1016/j.molcel.2012.10.025.
  53. T. Song, H.-K. Jeon, J.E. Hong, et al., Proton pump inhibition enhances the cytotoxicity of paclitaxel in cervical cancer, Cancer Res. Treat. (2016)
  54. Syrosingopine sensitizes cancer cells to killing by metformin Don Benjamin, Marco Colombi, Sravanth K. Hindupur, Charles Betz, Heidi A. Lane, Mahmoud Y. M. El-Shemerly Min Lu, Luca Quagliata, Luigi Terracciano, Suzette Moes, Timothy Sharpe, Aleksandra Wodnar-Filipowicz, Christoph Moroni, Michael N. Hall December 2016 in Science Advances
  1. H. Song, M. Fares, K.R. Maguire, A. Siden, Cytotoxic effects of tetracyclineanalogs (doxycycline, minocycline and col-3) in acute myeloid leukemiaHL-60 cells, PLoS One (2014),
  2. Zhang J, Sun X, Wang L, et al. Artesunate-induced mitophagy alters cellular redox status. Redox Biol. 2018;19:263–273. doi:10.1016/j.redox.2018.07.025
  3. T. Kloskowski, N. Gurtowska, J. Olkowska, J.M. Nowak, J. Adamowicz, J.Tworkiewicz, et al., Ciprofloxacin is a potential topoisomerase II inhibitor forthe treatment of NSCLC, Int. J. Oncol. 41 (6) (2012) 1943–1949, http://dx.doi.org/10.3892/ijo.2012.1653.
  4. Artesunate Induces Cell Death in Human Cancer Cells via Enhancing Lysosomal Function and Lysosomal Degradation of Ferritin* Nai-Di Yang‡1, Shi-Hao Tan‡,§1, Shukie Ng‡, Yin Shi‡1, Jing Zhou‡, Kevin Shyong Wei Tan, Wai-Shiu Fred Wong‖ and Han-Ming Shen doi: 10.1074/jbc.M114.564567November 28, 2014The Journal of Biological Chemistry289, 33425-33441
  1. Glasauer, N.S. Chandel, Targeting antioxidants for cancer therapy, Biochem.Pharmacol. 92 (1) (2014) 90–101.
  1. A.R. Mendelsohn, J.W. Larrick, Paradoxical effects of antioxidants on cancer, Rejuvenation Res. 17 (3) (2014) 306–311.
  2. G. Galati, O. Sabzevari, J.X. Wilson, P.J. O’Brien, Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics, Toxicology 177 (1) (2002) 91–104.
  3. Plant flavone apigenin: An emerging anticancer agent. Shankar E, Goel A, Gupta K, Gupta S. Curr Pharmacol Rep. 2017 Dec; 3(6):423-446. Epub 2017 Oct 14.
  4. G. Galati, A. Lin, A.M. Sultan, P.J. O’Brien, Cellular and in vivo hepatotoxicity caused by green tea phenolic acids and catechins, Free Radic. Biol. Med. 40 (4) (2006) 570–580.
  5. Daruwalla J, Christophi C (2006) Hyperbaric oxygen therapy for malignancy: a review. World J Surg 30:2112–2131
  6. Kawasoe Y, Yokouchi M, Ueno Y, Iwaya H, Yoshida H, Komiya S (2009) Hyperbaric oxygen as a chemotherapy adjuvant in the
  7. treatment of osteosarcoma. Oncol Rep 22:1045–1050
  8. Kerbel RS, Kamen BA. The anti‑angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423‑36.
  9. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4 (+) 25+T regulatory cell function
  10. implicated in enhanced immune response by low‑dose cyclophosphamide. Blood 2005;105:2862‑8
  11. Bahl A, Bakhshi S. Metronomic chemotherapy in progressive pediatric malignancies: Old drugs in new package. Indian J Pediatr 2012;79:1617‑22
  12. San-Millán, I.; Brooks, G.A. Reexamining cancer metabolism: Lactate production for carcinogenesis could be the purpose and explanation of the Warburg Effect. Carcinogenesis 2017, 38, 119–133.
  13. Luc, R.; Tortorella, S.M.; Ververis, K.; Karagiannis, T.C. Lactate as an insidious metabolite due to the Warburg effect. Mol. Biol. Rep. 2015, 42, 835–840